Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B9-MMAE
- Development stage
- Preclinical
- Lead developer
- Fudan University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**B9-MMAE** is an antibody-drug conjugate composed of a human single-domain antibody (UdAb) called B9, which specifically binds to CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule 5), conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a valine-citrulline (vc) cleavable linker. The conjugate is designed for selective antitumor action: after B9 binds CEACAM5 on tumor cells, B9-MMAE is internalized, and MMAE is released intracellularly to inhibit tubulin polymerization, thereby blocking cell division and inducing cell death. Preclinical studies have demonstrated potent, target-specific cytotoxicity against CEACAM5-positive colorectal, pancreatic, and gastric cancer cell lines, and in xenograft models, significant tumor growth inhibition without notable toxicity was observed. The developer is Fudan University[3][5].
- Other names
- UdADC B9-MMAE
02
Targets
TUBB (Tubulin (alpha and beta subunits))CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on B9-MMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B9-MMAE.